The Catalogue Position: A Blend Is Not a Standard Research Item
A small UK biotech bench may ask for a fixed peptide blend—two or more lyophilised research peptides combined at a defined ratio—because an in-vitro assay needs a repeatable starting composition. The request can seem modest: a few vials, a stated ratio and a batch record for the bench file. A supplier may still decline. The reason is usually not the size of the bench or the apparent simplicity of the order. It is that a fixed blend sits outside the supplier’s standard catalogue, documentation and compliance model. Research Sciences’ published FAQs state that the shop does not supply blended peptides, citing the Ipamorelin plus CJC-1295 example, and recommends buying peptides individually and combining them only within a controlled experimental design.
Catalogue items are discrete, documented units. A standard listing has a SKU, a vial format, a batch-linked Certificate of Analysis and storage instructions. The homepage describes independently tested compounds, batch-level analytical verification for purity, identity and contaminant screening, and transparent CoAs; the FAQ says every product includes a CoA for HPLC purity and identity. A fixed blend creates a new composition. Each component may be documented in isolation, but the finished mixture raises different identity, homogeneity and traceability questions. The supplier would need a defensible route to document the blend as a batch—not merely place two certificates side by side. A responsible supplier may refuse rather than improvise that record.
Compliance wording matters. Research-use-only materials are strictly for controlled laboratory and analytical research. They are not medicines, medical devices, injectables, treatments or food supplements under UK law, and they are not for human or veterinary use, consumption, administration or clinical application. The shop states that it does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and that orders inconsistent with its compliance standards may be refused. If a blend request is framed around a clinical, therapeutic or personal-use outcome rather than an in-vitro laboratory workflow, refusal becomes much more likely. For a small bench, the practical lesson is to separate a legitimate assay requirement from wording that signals an unsupported use. The materials remain not for human or veterinary use.
A small order is not the problem; an unsupported configuration is. A fixed blend also complicates storage and handling. Lyophilised peptides are typically stored at −20°C or below, sealed with desiccant and protected from moisture, heat and light; reconstituted material is less stable and should be kept at 2–8°C for short-term laboratory use, with repeated freeze–thaw cycles avoided. A bespoke mixed lot can add new stability and handling variables that the supplier did not design for.
Documentation, Traceability and the Small-Bench Bottleneck
Documentation is often the decisive issue. A materials manager needs a clear chain from the vial in the freezer to the CoA in the bench file. Research Sciences’ published position is that CoAs are linked to supported products and that the specific batch document should be opened and checked. The homepage lists “CoAs Janoshik Analytical Reports”, but that wording is a starting point: the researcher should verify the actual batch CoA, rather than treating a headline claim as a substitute for the document. A fixed blend would combine two or more catalogue references, potentially with separate Internal Test References. That makes the paper trail harder to reconcile, especially when a small bench is trying to keep assay records tight.
Traceability is not administrative clutter. The FAQs note that restocked products may carry the same Internal Test Reference as earlier stock, and that an ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colours and other packaging may vary, and cap colour is not an indicator of identity, analytical quality or manufacturing origin. Vial labels use a reference format combining SKU code and expiry date, such as BPC10-03/27, linked to the corresponding CoA. A blended vial would need an equivalent, unambiguous link to every component and every batch. If the supplier cannot provide that, refusing the blend is more defensible than issuing a document that implies more traceability than exists.
Testing and handling add further variables. The shop describes full-spectrum testing as purity, identity, heavy metals and endotoxin evaluation of submitted samples, with HPLC testing for purity and identity. A fixed blend would require a testing rationale for the mixture, not just for the separate vials. Small benches often have limited freezer capacity, limited analytical time and a narrow window between preparation and assay. A single mixed vial may also increase freeze–thaw events or introduce an extra handling step before the in-vitro workflow. These are practical reasons why a supplier may prefer separate catalogue vials. The materials are not for human or veterinary use.
Order Practice, Compliance Filters and Practical Routes Around a Refusal
Refusal can also be an order-practice decision. The shop’s compliance wording says that products are supplied for controlled laboratory and analytical research only, and that the purchaser is responsible for lawful use, safe handling, storage, disposal, COSHH and laboratory safety, and for checking suitability for the intended research application. A request for a fixed blend may sound routine to a bench, but to a supplier it can look like a custom formulation without a standard quality route. The supplier does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance. If an enquiry drifts towards clinical, diagnostic or personal-use language, the compliance filter is likely to close. A bench should describe the work as an in-vitro assay, state the laboratory context and accept that not every custom mixture can be supplied.
Fulfilment terms can reinforce that caution. Published terms describe next-working-day dispatch, tracked UK delivery and Royal Mail Tracked 24 as an estimate rather than a guarantee; delivery times can vary in peak periods. No returns are accepted once dispatched, because of the specialist and perishable nature of the goods, with refunds only for damage, incorrect supply or quality issues as set out in the Refunds & Returns Policy. A bespoke blend is difficult to restock or reassign if an order is refused, delayed or unsuitable. Payment by bank or Open Banking, rather than card, is another administrative step, though it is rarely the main reason for refusal. The central point is that a non-standard blend carries non-standard documentation and handling burdens.
A practical route is to buy individual catalogue vials and combine only within a controlled experimental design. A bench reviewing the live catalogue through Peptides uk can check examples such as Ipamorelin 5mg, CJC-1295 (No DAC) 5mg, BPC-157 10mg, TB-500 5mg or MT-1 10mg, then confirm the batch CoA and storage conditions before planning any in-vitro work. The free reconstitution calculator is described for laboratory research use only and must not be used for human or veterinary dosing. Always reconfirm current catalogue wording, purity statements, CoAs, dispatch estimates and payment options on the live site and on the batch document. These materials are not for human or veterinary use.
